Patient-Derived Stem Cell Models in SPAST HSP: Disease Modelling and Drug Discovery
1
Department of Neurogenetics, Kolling Institute of Medical Research, The University of Sydney, Sydney, NSW 2065, Australia
2
Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia
*
Author to whom correspondence should be addressed.
Brain Sci. 2018, 8(8), 142; https://doi.org/10.3390/brainsci8080142
Received: 15 June 2018 / Revised: 18 July 2018 / Accepted: 25 July 2018 / Published: 31 July 2018
(This article belongs to the Special Issue Advances in Genetics of Hereditary Spastic Paraplegia)
Hereditary spastic paraplegia is an inherited, progressive paralysis of the lower limbs first described by Adolph Strümpell in 1883 with a further detailed description of the disease by Maurice Lorrain in 1888. Today, more than 100 years after the first case of HSP was described, we still do not know how mutations in HSP genes lead to degeneration of the corticospinal motor neurons. This review describes how patient-derived stem cells contribute to understanding the disease mechanism at the cellular level and use this for discovery of potential new therapeutics, focusing on SPAST mutations, the most common cause of HSP.
View Full-Text
Keywords:
neurodegeneration; microtubule; organelle transport; peroxisome; spastic paraplegia; SPG4; SPAST; spastin
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Wali, G.; Sue, C.M.; Mackay-Sim, A. Patient-Derived Stem Cell Models in SPAST HSP: Disease Modelling and Drug Discovery. Brain Sci. 2018, 8, 142.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
